Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 16/20 | 1.00 |
| ▸ | LCK | P06239 | 15/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 14/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | INSR | P06213 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | TEC | P42680 | 1/20 | 1.00 |
| ▸ | TXK | P42681 | 1/20 | 1.00 |
| ▸ | BMX | P51813 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 1.00 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29742712 | 1.00 | ITK (1.00) | ITKLCKAURKBEGFRINSR | |
| SCHEMBL141374 | 1.00 | ITK (1.00) | ITKLCKAURKBEGFRINSR | |
| SCHEMBL140282 | 0.93 | ITK (0.87) | ITKLCKAURKBEGFRINSR | |
| SCHEMBL140283 | 0.93 | ITK (0.87) | ITKLCKAURKBEGFRINSR | |
| SCHEMBL143582 | 0.92 | ITK (0.85) | ITKLCKAURKBEGFRINSR | |
| SCHEMBL143583 | 0.92 | ITK (0.85) | ITKLCKAURKBEGFRINSR | |
| SCHEMBL140894 | 0.92 | ITK (1.00) | ITKLCKAURKBEGFRINSR | |
| SCHEMBL138293 | 0.92 | ITK (0.85) | ITKLCKAURKBEGFRINSR | |
| SCHEMBL140893 | 0.92 | ITK (1.00) | ITKLCKAURKBEGFRINSR | |
| SCHEMBL138294 | 0.92 | ITK (0.85) | ITKLCKAURKBEGFRINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340412-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | IOVANCE BIOTHERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230340412-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | IOVANCE BIOTHERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230165898-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEROF | IOVANCE BIOTHERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230165898-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEROF | IOVANCE BIOTHERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20220133795-A1 | Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof | IOVANCE BIOTHERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220118011-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20200347350-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | IOVANCE BIOTHERAPEUTICS INC (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200224161-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2408769-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | Glaxo Group Limited (GB) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106016-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200224161-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | PBK, MALT1, BCL9L | ITK 264/4885LCK 34/4885AURKB 1763/4885 |
| US-20230340412-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | LTK, LIFR, PBK | ITK 372/4885LCK 24/4885AURKB 2206/4885 |
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | DTYMK, ITK, DCK | ITK 2/4885LCK 189/4885AURKB 53/4885 |
| US-20230165898-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEROF | CD47, LTK, PBK | ITK 1196/4885LCK 61/4885AURKB 1757/4885 |
| US-20220133795-A1 | Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof | PBK, LTK, CD47 | ITK 770/4885LCK 55/4885AURKB 2496/4885 |
| US-20200347350-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | LTK, LIFR, PBK | ITK 372/4885LCK 24/4885AURKB 2206/4885 |
| US-20220118011-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | ICOS, PBK, IL2 | ITK 83/4885LCK 12/4885AURKB 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.